BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Indigo Biosciences, Inc.'s New MitoVir Platform is a Novel Approach to Mitochondrial Toxicity


3/12/2013 12:48:58 PM

(State College, PA; March 12, 2013) – A number of clinical studies involving antiviral compounds that were recently halted or put on hold may have benefited from a new series of assays being introduced by INDIGO Biosciences. Called the MitoVir Platform, the assays evaluate mitochondrial toxicity by examining inhibition of the ribonucleoside triphosphates that are substrates for the human mitochondrial RNA polymerase (POLRMT).

The MitoVir Platform is based on research conducted by Dr. Jamie Arnold, Dr. Craig Cameron and colleagues at Pennsylvania State University that demonstrates that antiviral drugs can get not only into the viral RNA, but also into healthy mitochondrial RNA.

"The cellular mitochondria that are responsible for making ATP are affected by these compounds, which is why we see adverse side effects," Cameron said, noting that some individuals are more sensitive to the effects of antiviral drugs. “We hope this method will prevent adverse events in the clinic, at least until prescreening of patients to identify those with mitochondrial diseases becomes a part of the process."

According to INDIGO President and CEO Jack Vanden Heuvel, the MitoVir Platform includes three assays: ATP production, mitochondrial RNA production and POLRMT activity.

“We now have a method of predicting adverse side effects to antiviral drugs in the safety of a laboratory setting, rather than in clinical trials where patients may be placed at risk,” he said. “We’re certain this will be a significant advance in the development of this important class of antiviral compounds.”

For more information on the MitoVir Platform assays, visit INDIGOBiosciences.com to review the MitoVir Platform or call (814) 234-1919.

About INDIGO Biosciences, Inc.

INDIGO Biosciences, Inc. offers products and services focused on nuclear receptors for the drug discovery and biosciences industries. The company’s unique processing method to cryo-preserve nuclear receptor reporter cells, named CryoMiteTM, provides long-term cryo-preservation of cells for shipping and storage and on-demand use. INDIGO Biosciences provides quality screening services and active ingredient determination for clients within the pharmaceutical, biotechnology, food, agriculture and nutraceutical industries and for government research agencies and academic researchers.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES